News
Novo Nordisk, Maker of Obesity Drug Wegovy
Digest more
It's no secret that Novo Nordisk ( NVO -1.69%) and Eli Lilly ( LLY 1.57%) are toughing it out in the battle of the weight ...
Denmark's economy remains robust despite job cuts at Novo Nordisk , the finance minister told Reuters on Wednesday, ...
Novo Nordisk is deeply undervalued despite stellar fundamentals: 18% sales growth, a 29% OP jump, and a rock-solid balance ...
Danish pharmaceutical giant Novo Nordisk announced Wednesday that it would cut 11 percent of its workforce, as the maker of ...
Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1 medication approved to treat metabolic associated steatohepatitis, a serious condition marked by liver scarring. The FDA ...
Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback